Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02696 HENLIUS-B > Detailed Quotes

02696 HENLIUS-B

11.400
-0.100-0.87%
Closed 09/30 16:08 CCT
High
12.080
Open
11.620
Turnover
1.30M
Low
11.160
Pre Close
11.500
Volume
112.80K
Market Cap
6.20B
P/E(TTM)
Loss
52wk High
34.050
Shares
543.49M
P/E(Static)
Loss
52wk Low
11.160
Float Cap
1.86B
Bid/Ask %
76.79%
Historical High
67.050
Shs Float
163.43M
Volume Ratio
1.98
Historical Low
11.160
Dividend TTM
--
Div Yield TTM
--
P/B
2.55
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.07%
Amplitude
8.00%
Avg Price
11.507
Lot Size
100
Float Cap
1.86B
Bid/Ask %
76.79%
Historical High
67.050
Shs Float
163.43M
Volume Ratio
1.98
Historical Low
11.160
Dividend TTM
--
P/B
2.55
Dividend LFY
--
Turnover Ratio
0.07%
Amplitude
8.00%
Avg Price
11.507
Lot Size
100
Price Forecast

No Data

News

Comment

Company Overview More
Shanghai Fuhong Hanlin Biotechnology Co., Ltd. is a Chinese company mainly engaged in the research, development, production and sales of monoclonal antibody products. The company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) bioanalogue HLX02, trimethoprim (adamumab) bioanalogue HLX03 and Avetine (bevacizumab) bioanalogue HLX04, as well as candidate biological innovation drugs. It includes HLX06 (a new type of VEGFR2 inhibitor), HLX07 (a kind of EGFR inhibitor), HLX10 (a new type of PD-1 inhibitor), HLX20 (a new type of PD-L1 inhibitor) and HLX22 (a new type of HER2 inhibitor). The company also provides related technical services. The company mainly operates in China and the United States.
CEO: Wenjie Zhang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...